Circulating Biomarkers in Advanced Renal Cell Carcinoma: Clinical Applications
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Circulating Biomarkers in Advanced Renal Cell Carcinoma: Clinical Applications
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 14, Issue 3, Pages 221-229
Publisher
Springer Nature
Online
2012-03-20
DOI
10.1007/s11912-012-0231-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis
- (2017) B. J. Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor
- (2017) T. E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (Pts) with advanced or metastatic renal cell cancer (mRCC) treated in phase III trials of pazopanib (PAZO).
- (2017) Y. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma
- (2014) S. Kusmartsev et al. JOURNAL OF IMMUNOLOGY
- A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
- (2011) A. J. Zurita et al. ANNALS OF ONCOLOGY
- Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment
- (2011) Andrea Mancuso et al. BJU INTERNATIONAL
- Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
- (2011) Viktor Gruenwald et al. BMC CANCER
- Levels of circulating CD45dimCD34+VEGFR2+ progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
- (2011) F Farace et al. BRITISH JOURNAL OF CANCER
- Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
- (2011) R S Bhatt et al. BRITISH JOURNAL OF CANCER
- Effect of Low-Fat Diets on Plasma Levels of NF- B-Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer
- (2011) J. V. Heymach et al. Cancer Prevention Research
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
- (2011) Judith Manola et al. CLINICAL CANCER RESEARCH
- 1404 POSTER DISCUSSION Baseline (BL) IL-6, IL-8, and VEGF as Predictive and Prognostic Markers for Overall Survival (OS) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts) Treated in a Phase III Trial of Pazopanib (PAZO) Versus Placebo (PL)
- (2011) Y. Liu et al. EUROPEAN JOURNAL OF CANCER
- Systemic Therapy for Metastatic Non–Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions
- (2011) Simon Chowdhury et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
- (2011) James Finke et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Elusive Identities and Overlapping Phenotypes of Proangiogenic Myeloid Cells in Tumors
- (2010) Seth B. Coffelt et al. AMERICAN JOURNAL OF PATHOLOGY
- Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma
- (2010) Min-Han Tan et al. BMC CANCER
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma
- (2010) Alessandro Antonelli et al. CANCER GENETICS AND CYTOGENETICS
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Pazopanib
- (2010) P. G. Nikolinakos et al. CANCER RESEARCH
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
- (2010) Jennifer S. Ko et al. CANCER RESEARCH
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2010) C. Pena et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers
- (2010) A Lindauer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
- (2010) Martin E Gore et al. LANCET
- Alterations in VHL as potential biomarkers in renal-cell carcinoma
- (2010) Lucy Gossage et al. Nature Reviews Clinical Oncology
- Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib
- (2009) Laura Vroling et al. ANGIOGENESIS
- Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon- : association of pretreatment serum levels with survival
- (2009) A. J. Montero et al. ANNALS OF ONCOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Renal Cell Carcinoma Correlates with Prognosis
- (2009) K. Bluemke et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
- (2009) Paulo C. Rodriguez et al. CANCER RESEARCH
- Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma
- (2009) T. Klatte et al. CLINICAL CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- The High-Dose Aldesleukin (IL-2) “Select” Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High-Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma
- (2009) Jessica M. Clement et al. Clinical Genitourinary Cancer
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer
- (2009) Emer O. Hanrahan et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma
- (2009) Brian I Rini et al. LANCET
- Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
- (2008) M. M. Hipp et al. BLOOD
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
- (2008) John D. Gordan et al. CANCER CELL
- Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents
- (2008) Yuval Shaked et al. CANCER CELL
- Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival
- (2008) H. van Cruijsen et al. CLINICAL CANCER RESEARCH
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
- (2008) M. L. Nickerson et al. CLINICAL CANCER RESEARCH
- Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
- (2008) S. Kusmartsev et al. CLINICAL CANCER RESEARCH
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality Requirements
- (2008) C. M. Sturgeon et al. CLINICAL CHEMISTRY
- Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis
- (2008) D. Gao et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started